Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study...

The primary analysis of IMscin002 (NCT05171777) demonstrated that most patients preferred atezolizumab subcutaneous (SC) administration over intravenous (IV) administration; we report patient preference according to baseline characteristics, mean injection duration, and cumulative number of SC injections at each center from IMscin002.

In this phase 2, randomized, open-label, crossover trial, patients aged ≥18 years, with EGFR/ALK wild-type tumors and either PD-L1+ (≥ 1%) resected non-small cell lung cancer (NSCLC) (stage 2, 3a, or selected 3b; AJCC 8th edition) with prior chemotherapy and no evidence of recurrence, or untreated PD-L1-high (≥ 50%) stage 4 NSCLC were eligible. Patients, randomized 1:1, received atezolizumab IV or SC for three cycles before switching to the alternative formulation for another three cycles. Patients chose a formulation for the continuation period after cycle 6.

patient preference for atezolizumab SC/IV.

Among 179 patients randomized, demographics and characteristics were generally balanced between arms. Overall, 87/123 patients (70.7%) preferred atezolizumab SC, of whom 86.2% had a very/fairly strong preference compared with 69.2% of patients who preferred IV (n = 26/123, 21.1%). Patient preference for atezolizumab SC was independent of baseline characteristics and mean injection duration. A higher proportion of preference was seen in patients aged > 74 years (87.5%). A trend for a greater number of patients preferring atezolizumab SC over IV was seen in patients at centers where a higher number of cumulative injections (> 47 to ≤ 164) were administered before preference disclosure.

Most patients preferred atezolizumab SC regardless of baseline characteristics, mean injection duration, and cumulative number of SC injections. The trend for a stronger preference was higher among patients who preferred SC than those who preferred IV. Our findings suggest that the proportion of preference for atezolizumab SC over IV is highest in patients aged > 74 years, and that administrator's experience could be an important factor influencing patient preference.

NCT05171777.